NLRP3 inflammasome activation by imiquimod and CL097 is K+ efflux-independent
Imiquimod and CL097 inhibit NQO2 and Complex I
Imiquimod and CL097 trigger ROS and cysteine oxidation
NLRP3 activation by these molecules requires ROS, Complex I dysfunction, and NEK7